New CAR-T therapy takes on tough blood cancers

NCT ID NCT07312630

Recruiting now Disease control Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new cell therapy called LV009 for people with certain blood cancers (lymphoma and leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goal is to check safety and how the therapy behaves in the body, with only 19 participants enrolled so far.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LV009 injection (a type of CAR-T cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for people with certain blood cancers that have not responded to standard therapies.
What could go wrong: This is a very early, small trial (19 people) focused on safety and dosing. It may not show strong effectiveness, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia adult acute lymphoblastic leukemia non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ADULT NON HODGKIN LYMPHOMA (NHL)

Contacts and locations

Locations

PersonGen.Anke Cellular Therapeutice Co., Ltd.
RECRUITING

Hefei, Anhui, 230088, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.